帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案在合并晚期肝纤维化的丙型肝炎病毒感染血液透析患者中的有效性:病例报告
该研究纳入10例基因1a、1b或4型丙型肝炎病毒感染且存在不良应答预测因素(代偿性肝硬化7例或晚期纤维化且既往治疗失败3例)的血液透析患者,给予帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案(联合或不联合利巴韦林)每日治疗12或24周。全部患者均获得持续病毒学应答(治疗后第12周)。80%患者报告至少1次不良事件,以轻度疲劳和贫血最常见,观察到1例中度肝失代偿。
要点
- 10例血液透析合并基因1a、1b或4型丙型肝炎病毒感染患者接受帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案治疗。
- 全部患者均获得持续病毒学应答(治疗后第12周)。
- 80%患者报告至少1次不良事件,疲劳和轻度贫血最常见,见1例中度肝失代偿。
核心结论
- 帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案对合并代偿性肝硬化和/或既往治疗失败的基因1或4型丙型肝炎病毒感染血液透析患者有效且耐受性良好。
研究设计与样本
- 病例报告,纳入10例基因1a、1b或4型丙型肝炎病毒感染的血液透析患者,其中代偿性肝硬化7例、晚期纤维化且既往治疗失败3例。
主要发现
- 全部患者均获得持续病毒学应答(治疗后第12周)。
- 80%患者报告至少1次不良事件,疲劳和轻度贫血最常见,观察到1例中度肝失代偿。
关键数值与推荐
- 治疗为帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案(联合或不联合利巴韦林)每日给药,疗程12或24周。
- 治疗期间每4周以及治疗后第4周和第12周进行临床和病毒学评估。
临床怎么用
- 作者认为帕利瑞韦/利托那韦/奥比他韦/达萨布韦方案对合并代偿性肝硬化和/或既往治疗失败的基因1或4型丙型肝炎病毒感染血液透析患者有效且耐受性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80% of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus-infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.
引用
- Ponziani FR, Siciliano M, Lionetti R, et al. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Am J Kidney Dis. 2017. PMID: 28258770. doi:10.1053/j.ajkd.2017.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。